Aldeyra Therapeutics (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin has been promoted to the position of Chief Commercial Officer, effective immediately. In his new role, Mr. McMullin will oversee Aldeyra’s strategic initiatives, commercial planning activities, marketing, and commercial infrastructure development.
“Based on his deep understanding of orphan and large pharmaceutical markets, Dave is well positioned to lead our commercial development efforts,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “I look forward to working closely with Dave as he prepares for commercialization of our late-stage clinical pipeline.”
Mr. McMullin joined Aldeyra in May 2018 as Senior Vice President and Head of Corporate Development and Strategy, and has more than 20 years of experience leading commercialization, business development, and strategic planning operations in the biopharmaceutical industry. Prior to joining Aldeyra, Mr. McMullin was Group Vice President and Head of U.S. Internal Medicine at Shire plc, a $1.4 billioncommercial business unit. Mr. McMullin also ran Global Commercial Operations at Shire Plc and was an in-line Committee member, responsible for commercial performance and execution worldwide. Prior to his work at Shire, Mr. McMullin held roles of increasing responsibility in corporate strategy, marketing, sales, and operations at Novartis International AG. Mr. McMullin received an M.B.A. from Harvard Business School, and a Bachelor of Science degree from Brigham Young University.
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra’s product candidates have been approved for sale in the U.S. or elsewhere.
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra’s product candidates have been approved for sale in the U.S. or elsewhere.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.